ft836
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2025 (NCT07216105)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- MHC class I polypeptide-related sequence BImmunity, passive
MHC class I polypeptide-related sequence B (MICB) immunity, passive
- MHC class I polypeptide-related sequence AImmunity, passive
MICA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221032 | Phase 1 | Mar 31, 2026 | Medical College of Wisconsin |
| NCT07216105 | Phase 1 | Nov 4, 2025 | Fate Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fate Therapeutics | For profit | 1 | 1 | 1 | 2025 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2026 |
2 organizations
Page 1 / 1